Regenxbio (RGNX) Reports Q3 Loss, Beats Revenue Estimates

分组1 - Regenxbio reported a quarterly loss of $1.2 per share, which was better than the Zacks Consensus Estimate of a loss of $1.38, representing an earnings surprise of +13.04% [1] - The company posted revenues of $29.73 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 23.73%, compared to $24.2 million in the same quarter last year [2] - Over the last four quarters, Regenxbio has surpassed consensus EPS estimates two times and topped revenue estimates once [2] 分组2 - The stock has gained approximately 50.2% since the beginning of the year, outperforming the S&P 500's gain of 15.6% [3] - The company's earnings outlook is crucial for future stock performance, with current consensus EPS estimates at $0.27 on $108.94 million in revenues for the upcoming quarter and -$2.43 on $228 million in revenues for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which Regenxbio belongs, is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook [8] 分组3 - The estimate revisions trend for Regenxbio was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]